DC-PLASTICS-INDUSTRY
20.2.2024 17:09:26 CET | Business Wire | Press release
The Plastics Industry Association (PLASTICS) will foster the continued growth of the bioplastics industry at its upcoming trade show, NPE: The Plastics Show. With more than 45 bioplastics related exhibitors on the show floor, NPE2024 is expected to be the largest gathering of bioplastics companies in the Americas. NPE2024 will take place from May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.
Companies such as NatureWorks, LG Chem, Evonik, LyondellBasell and more will display their latest developments in bioplastic polymers and additives across more than 47,000 square feet of exhibits. Attendees will explore the latest materials, technologies and processes offering innovative sustainability solutions creating a greener plastics economy while also hearing from a variety of sustainability experts, suppliers, and manufacturers on the all-new Sustainability Stage and in two Recycling and Sustainability Zones.
NPE2024 will provide a first-hand look into how sustainable plastics manufacturing is driving value creation for society, the environment and the industry. “We hope registrants will leave inspired to reduce plastic waste as they explore the latest in new end-market solutions, bioplastics, lightweighting, circularity, and more,” said Patrick Krieger, PLASTICS’ Vice President of Sustainability. “Our first-ever Sustainability Hub will highlight leaders in sustainability and include action-oriented displays in areas such as – renewable feedstocks, collection, sortation, energy efficient manufacturing and more – you will not want to miss it,” stated Krieger.
Additionally, made for plastic material suppliers, processors, equipment suppliers, and brands interested in investing in the bioplastics industry, PLASTICS will release it’s 2024 Bioplastics Market Watch Report on May 8 during NPE. The report will display the current market data compared to the 2018 report to show the market growth figures, policy implications and consumer perceptions affecting bioplastics businesses today.
“Through this report, we hope to gain a better understanding of consumer perceptions around bioplastic products, their sustainability value and functionality across our industry,” stated Dr. Perc Pineda, Ph.D., PLASTICS’ Chief Economist.
For more information about NPE2024 and to register, visit npe.org.
The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220376288/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
